Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05116254
Other study ID # M21SAD
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 18, 2022
Est. completion date July 1, 2028

Study information

Verified date April 2024
Source The Netherlands Cancer Institute
Contact Rick Haas, MD Prof
Phone +31205129111
Email r.haas@nki.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality treatment (CMT) by administering AZD1390 with or without durvalumab and RT concurrently treating newly diagnosed, non-metastatic soft tissue sarcoma patients with DDRi-based CMT, in the specific context of systemic toxicities, wound healing post-surgery and in defining the RP2D for the combinations to support further clinical evaluation.


Description:

Despite improvements in surgery and radiation for soft tissue sarcoma (STS) patients, local relapses remain an important event for these patients. Most STS subtypes are considered radioresistant and immune cold tumor due to a lack of T-cell infiltration. Investigations into radiosensitization mediated by combining systemic compounds with neoadjuvant radiotherapy (RT) may translate into an increased rate of pathological responses, an increased rate of R0 resections and thus fewer local relapses. RT is highly potent in inducing DNA damage. Normal cells are usually sufficiently able to repair this damage timely before the next fraction because of an intact DNA Damage Response (DDR) pathway. Frequently, tumor cells have (partial or complete) defects in the DDR pathways rendering them more sensitive to radiation than normal tissues. Inhibition of constituents of the DDR pathways may further widen the therapeutic window of fractionated radiotherapy, and combined with radiotherapy may result in increased tumor T-cell infiltration, creating an opportunity for immunotherapy. Clinical studies into radiosensitization of STS by combinations of radiotherapy and DDR inhibitors with or without immunotherapy are warranted. In this study the DDR candidate inhibitor is new drug candidate AZD1390 targeting ATM (Ataxia Telangiectasia Mutated). The immunotherapy candidate of this study is durvalumab (MEDI4736) targeting PD-L1 (programmed death-ligand 1).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 1, 2028
Est. primary completion date March 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, for which the standard treatment is a combination of RT and surgery (in other words deep seated and/or > 5cm in largest tumor diameter and/or an anticipated close resection margin and/or grade II/III according to the FNCLCC definition); - Patients staged by at least a CT scan of the chest (and a CT scan of the abdomen, if deemed indicated according to local practices, e.g. in case of a myxoid liposarcoma). Staging may also be performed by FDG-PET scanning and or total body MRI scans. This staging procedure should not reveal metastatic disease. If, however, a low metastatic burden is detected such that this does not preclude the application of both preoperative RT and definitive surgery, patients are allowed to participate; - WHO Performance Status = 2; - Able and willing to undergo preoperative RT; - Able and willing to undergo definitive surgery; - Able and willing to comply with regular follow-up visits; - Able and willing to swallow and retain oral medication; - Age = 18 years; - Body weight >30kg; - Must have a life expectancy of at least 12 weeks; - Adequate organ function as defined in Table 5; - Signed written informed consent prior to any study specific procedures or sampling Exclusion Criteria: - Patients with any type soft tissue sarcoma located above the clavicles. - Prior malignancies; except another malignancy and disease-free for = 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma; - Patients with recurrent sarcomas who underwent prior RT to the target lesion (if the primary sarcoma was managed by surgery only and no perioperative RT, patients are eligible); - Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), bone sarcomas; - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial; - Female patients who are pregnant or breast feeding; - Intention to perform an isolated limb perfusion, instead of a tumor resection; - Neoadjuvant chemotherapy to be scheduled between end of RT and definitive surgery is not allowed. (neoadjuvant chemotherapy before start of study RT is allowed); - Concomitant treatment with medicines listed as 'prohibited' or 'excluded'; - Treatment with moderate and strong inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort); Additional criteria for durvalumab plus AZD1390: - Past medical history of allogenic organ transplantation; - Past medical history of leptomeningeal carcinomatosis; - Past medical history or active autoimmune or inflammatory disorders - History or presence of primary immunodeficiency - Presence of active hepatitis infections or HIV - Treatment with or prior use of immunosuppressive medication within 2 weeks before the start of treatment - Prior treatment with anti-PD-1, anti PD-L1 or anti CTLA-4 immunotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
AZD1390 + radiotherapy
AZD1390 combined with preoperative radiotherapy
AZD1390 + durvlaumab + radiotherapy
AZD1390 combined with durvalumab and preoperative radiotherapy

Locations

Country Name City State
Netherlands Antoni van Leeuwenhoek Amsterdam

Sponsors (3)

Lead Sponsor Collaborator
The Netherlands Cancer Institute Leiden University Medical Center, University Medical Center Nijmegen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Drug safety all adverse events 2 years
Primary Drug tolerability adverse events and more specific woundhealing 30 days
Secondary Tumor regression pathological remission After 5 weeks of RT and DDRi-based drug treatment
Secondary Local control rates Histopathological response and MRI 2 years
Secondary Rate of R0 resection Histological examination of surgical specimens Directly after surgery
Secondary Rate of R1 resection Histological examination of surgical specimens Directly after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04656262 - Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients Phase 3
Recruiting NCT03077178 - Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over N/A
Not yet recruiting NCT06110650 - A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma N/A
Terminated NCT03735758 - Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib Phase 4
Not yet recruiting NCT03951571 - Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma Phase 2
Enrolling by invitation NCT03134742 - Radiation Effects on Bone
Not yet recruiting NCT06252727 - Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) Phase 1
Recruiting NCT04617327 - Pre-operative RadiothErapy for Soft Tissue SarcOmas N/A
Recruiting NCT06385288 - Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas N/A
Active, not recruiting NCT03526679 - Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Recruiting NCT04095208 - Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Phase 2
Recruiting NCT04330456 - Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy N/A
Completed NCT03833037 - Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
Completed NCT03056599 - Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Phase 1
Recruiting NCT05961761 - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Phase 2
Recruiting NCT06273852 - A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors Early Phase 1
Recruiting NCT05182164 - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Phase 2
Withdrawn NCT03104335 - Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial Phase 2